2013 EUROPEAN LEUKEMIANET RESPONSE CRITERIA VALIDATION IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH 3 AVAILABLE TKIS OUTSIDE CLINICAL TRIALS

被引：0

作者：

Breccia, M. ^{[1
]}

Pregno, P. ^{[2
]}

Annunziata, M. ^{[3
]}

Orlandi, E. ^{[4
]}

Gozzini, A. ^{[5
]}

Iurlo, A. ^{[6
]}

Bocchia, M. ^{[7
]}

Franceschini, L. ^{[8
]}

Montefusco, E. ^{[9
]}

Crugnola, M. ^{[10
]}

La Nasa, G. ^{[11
]}

Scortechini, A. R. ^{[12
]}

Sgherza, N. ^{[13
]}

Sica, S. ^{[14
]}

Alimena, G. ^{[1
]}

Saglio, G. ^{[15
]}

Specchia, G. ^{[16
]}

机构：

[1] Univ Roma La Sapienza, Hematol, Dept Cellular Biotechnol & Hematol, Rome, Italy

[2] Citta Salute & Sci Torino AOU, Hematol, Turin, Italy

[3] Cardarelli Hosp, Hematol, Naples, Italy

[4] Fdn IRCSS Policlin San Matteo, Hematol, Pavia, Italy

[5] Careggi Hosp AOU, Hematol, Florence, Italy

[6] Fdn IRCCS Ca Granda, Osped Maggiore Policlin, Hematol, Milan, Italy

[7] Univ Siena, Hematol, Siena, Italy

[8] Univ Roma Tor Vergata, Rome, Italy

[9] S Andrea Hosp, Hematol, Rome, Italy

[10] Parma AOU, Hematol, Parma, Italy

[11] Univ Cagliari, Hematol, Dept Med Sci, Cagliari, Italy

[12] Osped Riuniti Ancona, Hematol, Ancona, Italy

[13] IRCSS Ist Tumori Giovanni Paolo II, Hematol, Bari, Italy

[14] Univ Cattolica, Hematol, Rome, Italy

[15] Univ Turin, Hematol, Turin, Italy

[16] Policlin Consorziale Bari AOU, Hematol, Bari, Italy

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PB1827

引用

页码：738 / 739

页数：2

共 50 条

[41] Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia
Lo, Min-Yen
Tsai, Xavier Cheng-Hong
Lin, Chien-Chin
Tien, Feng-Ming
Kuo, Yuan-Yeh
Lee, Wan-Hsuan
Peng, Yen-Ling
Liu, Ming-Chih
Tseng, Mei-Hsuan
Hsu, Cheng-An
Chen, Jui-Che
Lin, Liang-In
Sun, Hsun-, I
Chuang, Yi-Kuang
Ko, Bor-Sheng
Tang, Jih-Luh
Yao, Ming
Chou, Wen-Chien
Hou, Hsin-An
Tien, Hwei-Fang
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (05) : 760 - 769
[42] Early prediction of stable MR4.5 by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib
Nee, Aisling
Lipton, Jeffrey H.
Kim, Dennis Dong Hwan
LEUKEMIA & LYMPHOMA, 2022, 63 (01) : 162 - 169
[43] BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Soverini, Simona
Hochhaus, Andreas
Nicolini, Franck E.
Gruber, Franz
Lange, Thoralf
Saglio, Giuseppe
Pane, Fabrizio
Mueller, Martin C.
Ernst, Thomas
Rosti, Gianantonio
Porkka, Kimmo
Baccarani, Michele
Cross, Nicholas C. P.
Martinelli, Giovanni
BLOOD, 2011, 118 (05) : 1208 - 1215
[44] Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
Rigolin, Gian Matteo
Olimpieri, Pier Paolo
Summa, Valentina
Celant, Simone
Scarfo, Lydia
Ballardini, Maria Pia
Urso, Antonio
Gambara, Silvia
Cavazzini, Francesco
Ghia, Paolo
Cuneo, Antonio
Russo, Pierluigi
HEMASPHERE, 2024, 8 (10):
[45] A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change
Rohon, Peter
Faber, Edgar
Divoka, Martina
Rozmanova, Sarka
Friedecky, David
Jarosova, Marie
Indrak, Karel
BIOMEDICAL PAPERS-OLOMOUC, 2013, 157 (02): : 181 - 188
[46] The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials
Molica, Matteo
Canichella, Martina
Fegatelli, Danilo Alunni
Colafigli, Gioia
Massaro, Fulvio
Latagliata, Roberto
Foa, Robin
Breccia, Massimo
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (12) : E661 - E664
[47] Prognostic significance of prior best response to imatinib in patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP)Treated with second generation tyrosine kinase inhibitors (TKIs)
Jabbour, Elias
Kantarjian, Hagop
Shan, Jenny
O'Brien, Susan
Wierda, William
Ravandi, Farhad
Borthakur, Gautant
Komblau, Steven
Walker, Brenda K.
Rios, Mary Beth
Cortes, Jorge
BLOOD, 2007, 110 (11) : 577A - 577A
[48] Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib
Lee, Sung-Eun
Choi, Soo Young
Kwak, Jae-Yong
Kim, Hawk
Kim, Jeong-A
Do, Young Rok
Kim, Hyeoung Joon
Park, Joon Seong
Chung, Joo Seop
Shin, Ho-Jin
Kim, Sung-Hyun
Kim, Dae-Young
Bunworasate, Udomsak
Choi, Chul Won
Cornejo Comia, Narcisa Sonia
Zang, Dae Young
Oh, Sukjoong
Jootar, Saengsuree
Reksodiputro, Ary Harryanto
Lee, Won Sik
Mun, Yeung-Chul
Kong, Jee Hyun
Caguioa, Priscilla B.
Park, Jinny
Jung, Chul Won
Kim, Dong-Wook
BLOOD, 2015, 126 (23)
[49] ACHIEVING EARLY OPTIMAL RESPONSE IS ASSOCIATED WITH BETTER HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB OR NILOTINIB AS FRONTLINE THERAPY
Jiang, Q.
Wang, H. B.
Mo, X. D.
Yu, L.
Huang, X. J.
HAEMATOLOGICA, 2015, 100 : 698 - 698
[50] The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib
Castagnetti, Fausto
Gugliotta, Gabriele
Breccia, Massimo
Iurlo, Alessandra
Levato, Luciano
Albano, Francesco
Vigneri, Paolo
Abruzzese, Elisabetta
Rossi, Giuseppe
Rupoli, Serena
Cavazzini, Francesco
Martino, Bruno
Orlandi, Ester
Pregno, Patrizia
Annunziata, Mario
Usala, Emilio
Tiribelli, Mario
Sica, Simona
Bonifacio, Massimiliano
Fava, Carmen
Gherlinzoni, Filippo
Bocchia, Monica
Soverini, Simona
Bochicchio, Maria Teresa
Cavo, Michele
Giovanni, Martinelli
Saglio, Giuseppe
Pane, Fabrizio
Baccarani, Michele
Rosti, Gianantonio
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (08) : 797 - 805

← 1 2 3 4 5 →